Disease Info Card

Localized Scleroderma

Information about Localized Scleroderma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Localized Scleroderma

Most recent studies have shown that Localized Scleroderma shares some biological mechanisms with atrophy, autoimmune-diseases, autoimmune-reaction, connective-tissue-diseases, dermatologic-disorders, diffuse-scleroderma, eosinophilia, fasciitis, fibrosis, generalized-morphea, lichen-disease, lichen-sclerosus-et-atrophicus, linear-scleroderma, lupus-erythematosus-systemic, lyme-disease, morphea, raynaud-disease, scleroderma, sclerosis, ulcer.

Among the many pathways, these few ones have gauged particular interests from scientists studying Localized Scleroderma, and have been seen in publications frequently: Aging, Cell Activation, Cell Adhesion, Cell Proliferation, Coagulation, Excretion, Fibrinolysis, Fibroblast Activation, Fibroblast Proliferation, Hypersensitivity, Immune Response, Localization, Lymphocyte Proliferation, Muscle Atrophy, Pathogenesis, Pigmentation, Reflex, Regeneration, Secretion, Wound Healing

Quite a number of genes have been found to play important roles in Localized Scleroderma, such as ACE, ATP6V0A1, C3, CD34, CDSN, FN1, IFNG, IL13, IL2, IL4, IL6, LIAS, MMP1, NT5E, RFC1, RFC2, RFC4, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.